Lanean...

ASCO 2016: highlights in breast cancer

At the 2016 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented. MA17.R was the first randomized phase III trial to evaluate the prolongation of adjuvant aromatase-inhibitor (AI) therapy from 5 to 10 years; while a significant reduction of disease-free surviva...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Memo
Egile Nagusiak: Bartsch, Rupert, Bergen, Elisabeth
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Vienna 2016
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5165027/
https://ncbi.nlm.nih.gov/pubmed/28058064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12254-016-0300-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!